LRRK2 and Cognitive impairment: Non-motor symptoms generally occurred at similar frequencies in patients with LRRK2 Gly2019Ser to those reported for patients with idiopathic PD; however, patients with LRRK2 Gly2019Ser had a lower risk of cognitive impairment and hyposmia than did patients with idiopathic PD.